Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. / Rossing, Maria; Yde, Christina Westmose; Sehested, Astrid; Østrup, Olga; Scheie, David; Dangouloff-Ros, Volodia; Geoerger, Birgit; Vassal, Gilles; Nysom, Karsten.

I: Cancer Genetics, Bind 212-213, 2017, s. 32-37.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Rossing, M, Yde, CW, Sehested, A, Østrup, O, Scheie, D, Dangouloff-Ros, V, Geoerger, B, Vassal, G & Nysom, K 2017, 'Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma', Cancer Genetics, bind 212-213, s. 32-37. https://doi.org/10.1016/j.cancergen.2017.03.005

APA

Rossing, M., Yde, C. W., Sehested, A., Østrup, O., Scheie, D., Dangouloff-Ros, V., ... Nysom, K. (2017). Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. Cancer Genetics, 212-213, 32-37. https://doi.org/10.1016/j.cancergen.2017.03.005

Vancouver

Rossing M, Yde CW, Sehested A, Østrup O, Scheie D, Dangouloff-Ros V o.a. Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. Cancer Genetics. 2017;212-213:32-37. https://doi.org/10.1016/j.cancergen.2017.03.005

Author

Rossing, Maria ; Yde, Christina Westmose ; Sehested, Astrid ; Østrup, Olga ; Scheie, David ; Dangouloff-Ros, Volodia ; Geoerger, Birgit ; Vassal, Gilles ; Nysom, Karsten. / Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. I: Cancer Genetics. 2017 ; Bind 212-213. s. 32-37.

Bibtex

@article{a1f277ef7dd24698ad6739ebfd4703ae,
title = "Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma",
abstract = "Meningiomas are rare in children. They are highly complex, harboring unique clinical and pathological characteristics, and many occur in patients with neurofibromatosis type 2. Hereby, we present a case of a two-year-old boy presented with a diagnostically challenging intraventricular tumor. It was incompletely resected 6 times over 14 months but kept progressing and was ultimately deemed unresectable. Histologically, the tumor was initially classified as schwannoma, but extensive international review concluded it was most likely an atypical meningioma, WHO grade II. Comprehensive genomic profiling revealed a TFG-ROS1 fusion, suggesting that ROS1-signaling pathway alterations were driving the tumor growth. In light of this new information, the possibility of a diagnosis of inflammatory myofibroblastic tumor was considered; however the histopathological results were not conclusive. This specific molecular finding allowed the potential use of precision medicine and the patient was enrolled in the AcS{\'e} phase 2 trial with crizotinib (NCT02034981), leading to a prolonged partial tumor response which is persisting since 14 months. This case highlights the value of precision cancer medicine in children.",
keywords = "crizotinib, fusion gene, meningioma, pediatric mesenchymal tumor, TFG-ROS1",
author = "Maria Rossing and Yde, {Christina Westmose} and Astrid Sehested and Olga {\O}strup and David Scheie and Volodia Dangouloff-Ros and Birgit Geoerger and Gilles Vassal and Karsten Nysom",
year = "2017",
doi = "10.1016/j.cancergen.2017.03.005",
language = "English",
volume = "212-213",
pages = "32--37",
journal = "Cancer genetics and cytogenetics",
issn = "0165-4608",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma

AU - Rossing, Maria

AU - Yde, Christina Westmose

AU - Sehested, Astrid

AU - Østrup, Olga

AU - Scheie, David

AU - Dangouloff-Ros, Volodia

AU - Geoerger, Birgit

AU - Vassal, Gilles

AU - Nysom, Karsten

PY - 2017

Y1 - 2017

N2 - Meningiomas are rare in children. They are highly complex, harboring unique clinical and pathological characteristics, and many occur in patients with neurofibromatosis type 2. Hereby, we present a case of a two-year-old boy presented with a diagnostically challenging intraventricular tumor. It was incompletely resected 6 times over 14 months but kept progressing and was ultimately deemed unresectable. Histologically, the tumor was initially classified as schwannoma, but extensive international review concluded it was most likely an atypical meningioma, WHO grade II. Comprehensive genomic profiling revealed a TFG-ROS1 fusion, suggesting that ROS1-signaling pathway alterations were driving the tumor growth. In light of this new information, the possibility of a diagnosis of inflammatory myofibroblastic tumor was considered; however the histopathological results were not conclusive. This specific molecular finding allowed the potential use of precision medicine and the patient was enrolled in the AcSé phase 2 trial with crizotinib (NCT02034981), leading to a prolonged partial tumor response which is persisting since 14 months. This case highlights the value of precision cancer medicine in children.

AB - Meningiomas are rare in children. They are highly complex, harboring unique clinical and pathological characteristics, and many occur in patients with neurofibromatosis type 2. Hereby, we present a case of a two-year-old boy presented with a diagnostically challenging intraventricular tumor. It was incompletely resected 6 times over 14 months but kept progressing and was ultimately deemed unresectable. Histologically, the tumor was initially classified as schwannoma, but extensive international review concluded it was most likely an atypical meningioma, WHO grade II. Comprehensive genomic profiling revealed a TFG-ROS1 fusion, suggesting that ROS1-signaling pathway alterations were driving the tumor growth. In light of this new information, the possibility of a diagnosis of inflammatory myofibroblastic tumor was considered; however the histopathological results were not conclusive. This specific molecular finding allowed the potential use of precision medicine and the patient was enrolled in the AcSé phase 2 trial with crizotinib (NCT02034981), leading to a prolonged partial tumor response which is persisting since 14 months. This case highlights the value of precision cancer medicine in children.

KW - crizotinib

KW - fusion gene

KW - meningioma

KW - pediatric mesenchymal tumor

KW - TFG-ROS1

U2 - 10.1016/j.cancergen.2017.03.005

DO - 10.1016/j.cancergen.2017.03.005

M3 - Journal article

C2 - 28449809

AN - SCOPUS:85018831129

VL - 212-213

SP - 32

EP - 37

JO - Cancer genetics and cytogenetics

JF - Cancer genetics and cytogenetics

SN - 0165-4608

ER -

ID: 189734344